# Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

> **NCT06863467** · PHASE1,PHASE2 · COMPLETED · sponsor: **Revelation Biosciences, Inc** · enrollment: 40 (actual)

## Conditions studied

- Renal Insufficiency, Chronic
- Chronic Kidney Disease stage3
- Chronic Kidney Disease stage4

## Interventions

- **DRUG:** Intravenous Gemini
- **DRUG:** Intravenous placebo

## Key facts

- **NCT ID:** NCT06863467
- **Lead sponsor:** Revelation Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-20
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-07-22
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863467, "Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06863467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*